India’s organised pharma retail market bounced back with double-digit growth in November, driven by high demand for derma and cardiac drugs, after months of subdued performance, reported TOI. Heavy pollution across several parts of the country also contributed to increased sales of respiratory medications , particularly Foracort , used for asthma and related conditions. Foracort emerged as the top-selling drug for the month, recording sales of Rs 82 crore with a 2% growth.
Antibiotic Augmentin secured the second spot with Rs 76 crore in sales and a 9% growth, while antidiabetic drug Glycomet GP ranked third with flat sales of Rs 69 crore. Among therapeutic categories, urology led the growth at 18%, followed by derma (16%), cardiac (13%), and pain-relief (13%) segments. Pain-relief medication Zerodol SP saw a remarkable 22% growth, while other high-performing drugs like Ryzodeg, Rosuvas, Cilacar, Rybelsus, and Duphalac posted over 20% month-on-month growth, as per the TOI report.
Sun Pharma maintained its leadership in the market with an 8% share of the Rs 2.28 lakh crore retail pharma sector. Cipla and Dr.
Reddy's also saw their market shares rise in November. Design Canva Magic Write: Ideas to Stunning Slides in No Time By - Prince Patni, Software Developer (BI, Data Science) View Program Web Development C++ Fundamentals for Absolute Beginners By - Metla Sudha Sekhar, IT Specialist and Developer View Program Web Development Mastering Full Stack Development: From Frontend t.
